Current Report Filing (8-k)
05 Oktober 2021 - 02:17PM
Edgar (US Regulatory)
0001477845 false 0001477845 2021-10-05
2021-10-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
October 5, 2021
ANNOVIS BIO, INC.
(Exact Name of Registrant as Specified in
Charter)
|
|
|
|
|
Delaware |
|
001-39202 |
|
26-2540421 |
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1055 Westlakes Drive,
Suite 300
Berwyn,
PA
19312
(Address of Principal Executive Offices, and Zip Code)
(610)
727-3913
Registrant’s Telephone Number, Including Area Code
Not
Applicable
(Former Name or Former Address, if Changed Since Last
Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
ANVS |
NYSE American |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General
Instruction A.2. below):
|
¨ |
Written communication
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 |
Regulation FD Disclosure. |
On October 5, 2021, Annovis Bio Inc. (the “Company”) issued a press
release announcing results from the completed dose response Phase 2
clinical trial of ANVS401. A copy of the Press Release is attached
to this Current Report on Form 8-K as Exhibit 99.1.
On October 5, 2021, at 9:00 am ET the Company will host an investor
conference call to discuss the results of the completed dose
response Phase 2 clinical trial of ANVS401. Interested parties can
participate through the following link:
https://russopr.zoom.us/j/87423723968. A copy of a presentation to
be referenced during the investor conference call is furnished as
Exhibit 99.2.
The information in this Item 7.01, Item 9.01, Exhibit 99.1 and
Exhibit 99.2 attached hereto shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, or
otherwise subject to the liability of such section, nor shall it be
deemed incorporated by reference in any filing of the Company under
the Securities Act of 1933 or the Securities Exchange Act of 1934,
regardless of any general incorporation language in such filing,
unless expressly incorporated by specific reference in such
filing.
Cautionary Statement Regarding Forward-Looking
Information
This current report on Form 8-K contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements other than those of historical
fact in the frequently asked questions documents are
forward-looking statements. Forward-looking statements may be
identified by terminology such as “believe,” “anticipate,” “plan,”
“may,” “intend,” “will,” “should,” “expect,” “estimate,”
“potential” and “continue” and similar expressions, including the
negative of these words, but not all forward-looking statements
contain these words. Forward-looking statements include, but are
not limited to, statements regarding the Company’s expectations and
timelines regarding the Company’s Phase 2a clinical trial and
expectations regarding current or future clinical trials.
Forward-looking statements are based on the Company’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate, including that clinical
trials may be delayed; that the data reported herein is only from a
Phase 2a study and subsequent clinical trials must be conducted;
and that any anticipated meeting with or presentation to the FDA
may be delayed. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various important factors, including, without limitation, the
failure of preliminary data to predict final study results and
impacts from the COVID-19 pandemic and the other important factors
other risks and uncertainties are described more fully in the
section titled “Risk Factors” in the Annual Report on Form 10-K for
the year ended December 31, 2020 filed with the Securities and
Exchange Commission (“SEC”) and elsewhere in our filings and
reports with the SEC. Forward-looking statements speak as of the
date they are made, and the Company undertakes no obligation to
update them except as may be required under applicable law.
Item 9.01 |
Financial Statements and
Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
ANNOVIS BIO,
INC. |
|
|
|
Date: October 5, 2021 |
By: |
/s/ Jeffrey McGroarty |
|
|
Name: Jeffrey McGroarty |
|
|
Title: Chief Financial Officer |
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
Von Apr 2022 bis Mai 2022
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
Von Mai 2021 bis Mai 2022